Explore
Validate
LearnH00057509-M01
antibody from Novus Biologicals
Targeting: MTUS1
ATBP, ATIP1, ATIP3, DKFZp586D1519, FLJ14295, ICIS, KIAA1288, MP44, MTSG1
Western blot
ImmunocytochemistryAntibody data
- Antibody Data
- Antigen structure
- References [8]
- Comments [0]
- Validations
- Western blot [2]
- ELISA [1]
Submit
Validation data
Reference
Comment
Report error
- Product number
- H00057509-M01 - Provider product page
- Provider
- Novus Biologicals
- Proper citation
- Novus Cat#H00057509-M01, RRID:AB_2148406
- Product name
- Mouse Monoclonal MTUS1 Antibody
- Antibody type
- Monoclonal
- Description
- IgG purified. MTUS1 - mitochondrial tumor suppressor 1
- Reactivity
- Human, Mouse
- Host
- Mouse
- Isotype
- IgG
- Vial size
- 0.1 mg
- Storage
- Aliquot and store at -20C or -80C. Avoid freeze-thaw cycles.
Submitted references Combinatorial expression of microtubule-associated EB1 and ATIP3 biomarkers improves breast cancer prognosis.
Angiotensin II type 2 receptor-interacting protein 3a suppresses proliferation, migration and invasion in tongue squamous cell carcinoma via the extracellular signal-regulated kinase-Snai2 pathway.
Genetic and functional characterization of clonally derived adult human brown adipocytes.
Loss of MTUS1/ATIP expression is associated with adverse outcome in advanced bladder carcinomas: data from a retrospective study.
Expression and role of the angiotensin II AT2 receptor in human prostate tissue: in search of a new therapeutic option for prostate cancer.
Down-regulation of tumor suppressor MTUS1/ATIP is associated with enhanced proliferation, poor differentiation and poor prognosis in oral tongue squamous cell carcinoma.
LOH and copy neutral LOH (cnLOH) act as alternative mechanism in sporadic colorectal cancers with chromosomal and microsatellite instability.
8p22 MTUS1 gene product ATIP3 is a novel anti-mitotic protein underexpressed in invasive breast carcinoma of poor prognosis.
Rodrigues-Ferreira S, Nehlig A, Monchecourt C, Nasr S, Fuhrmann L, Lacroix-Triki M, Garberis I, Scott V, Delaloge S, Pistilli B, Vielh P, Dubois T, Vincent-Salomon A, André F, Nahmias C
Breast cancer research and treatment 2019 Feb;173(3):573-583
Breast cancer research and treatment 2019 Feb;173(3):573-583
Angiotensin II type 2 receptor-interacting protein 3a suppresses proliferation, migration and invasion in tongue squamous cell carcinoma via the extracellular signal-regulated kinase-Snai2 pathway.
Zhao T, He Q, Liu Z, Ding X, Zhou X, Wang A
Oncology letters 2016 Jan;11(1):340-344
Oncology letters 2016 Jan;11(1):340-344
Genetic and functional characterization of clonally derived adult human brown adipocytes.
Shinoda K, Luijten IH, Hasegawa Y, Hong H, Sonne SB, Kim M, Xue R, Chondronikola M, Cypess AM, Tseng YH, Nedergaard J, Sidossis LS, Kajimura S
Nature medicine 2015 Apr;21(4):389-94
Nature medicine 2015 Apr;21(4):389-94
Loss of MTUS1/ATIP expression is associated with adverse outcome in advanced bladder carcinomas: data from a retrospective study.
Rogler A, Hoja S, Giedl J, Ekici AB, Wach S, Taubert H, Goebell PJ, Wullich B, Stöckle M, Lehmann J, Petsch S, Hartmann A, Stoehr R
BMC cancer 2014 Mar 20;14:214
BMC cancer 2014 Mar 20;14:214
Expression and role of the angiotensin II AT2 receptor in human prostate tissue: in search of a new therapeutic option for prostate cancer.
Guimond MO, Battista MC, Nikjouitavabi F, Carmel M, Barres V, Doueik AA, Fazli L, Gleave M, Sabbagh R, Gallo-Payet N
The Prostate 2013 Jul;73(10):1057-68
The Prostate 2013 Jul;73(10):1057-68
Down-regulation of tumor suppressor MTUS1/ATIP is associated with enhanced proliferation, poor differentiation and poor prognosis in oral tongue squamous cell carcinoma.
Ding X, Zhang N, Cai Y, Li S, Zheng C, Jin Y, Yu T, Wang A, Zhou X
Molecular oncology 2012 Feb;6(1):73-80
Molecular oncology 2012 Feb;6(1):73-80
LOH and copy neutral LOH (cnLOH) act as alternative mechanism in sporadic colorectal cancers with chromosomal and microsatellite instability.
Melcher R, Hartmann E, Zopf W, Herterich S, Wilke P, Müller L, Rosler E, Kudlich T, Al-Taie O, Rosenwald A, Katzenberger T, Scholtka B, Seibold S, Rogoll D, Scheppach W, Scheurlen M, Lührs H
Carcinogenesis 2011 Apr;32(4):636-42
Carcinogenesis 2011 Apr;32(4):636-42
8p22 MTUS1 gene product ATIP3 is a novel anti-mitotic protein underexpressed in invasive breast carcinoma of poor prognosis.
Rodrigues-Ferreira S, Di Tommaso A, Dimitrov A, Cazaubon S, Gruel N, Colasson H, Nicolas A, Chaverot N, Molinié V, Reyal F, Sigal-Zafrani B, Terris B, Delattre O, Radvanyi F, Perez F, Vincent-Salomon A, Nahmias C
PloS one 2009 Oct 1;4(10):e7239
PloS one 2009 Oct 1;4(10):e7239
No comments: Submit comment
Supportive validation
- Submitted by
- Novus Biologicals (provider)
- Main image
- Experimental details
- Western Blot: MTUS1 Antibody (1C7) [H00057509-M01] - Western Blot analysis of MTUS1 expression in K-562 ( Cat # L009V1 ).
- Submitted by
- Novus Biologicals (provider)
- Main image
- Experimental details
- Western Blot: MTUS1 Antibody (1C7) [H00057509-M01] - MTUS1 monoclonal antibody (M01), clone 1C7. Analysis of MTUS1 expression in human ovarian cancer.
Supportive validation
- Submitted by
- Novus Biologicals (provider)
- Main image
- Experimental details
- Sandwich ELISA: MTUS1 Antibody (1C7) [H00057509-M01] - Detection limit for recombinant GST tagged MTUS1 is approximately 0.3ng/ml as a capture antibody.
